PMEL and melanoma: Antibodies against CD3, CD20, and HMB45 plus S100B were used for VM and used to segment the ROI in B cells (CD20), T cells (CD3), and melanoma cells (PMEL/S100B), and the tumors were categorized into tumors with and without TLS.